Interference No. 103,586
OR
An assay for identifying compounds that inhibit ras oncogene activity, comprising:
(a) reacting a protein or peptide substrate having a CAAX motif with farnesyl
pyrophosphate and farnesyl-protein transferase in the presence of a test substance, and
(b) detecting whether the farnesyl residue is incorporated into the protein or peptide
substrate, in which the ability of the test substance to inhibit ras oncogene activity is
indicated by a decrease in the incorporation of the farnesyl residue into the protein or
peptide substrate as compared to the amount of the farnesyl residue incorporated into the
protein or peptide substrate in the absence of the test substance.
Barbacid claims 1-19 and Brown claims 37, 39, 41, 42, 53, 54, 57, 58 and 60
correspond to the count.
During the preliminary motion stage of this proceeding, Barbacid filed a motion for
judgment (Barbacid Motion No. 1) against Brown on the grounds that the Brown claims are
unpatentable under 35 U.S.C. § 135(b), which motion was denied. Brown filed a motion
for judgment (Brown Motion No. 1) against Barbacid that Barbacid claims are
unpatentable under 35 U.S.C. § 112, first paragraph for lack of best mode, which motion
was denied. Lastly, Brown filed motion No. 5 pursuant to 37 C.F.R. § 1.633(c)(2) to
amend claims 37, 39 and 54 and to add claims 57-60 and Motion No. 6 pursuant to 37
C.F.R. § 1.633(c)(3) to designate Barbacid claims 7, 14, and 17-19 as corresponding to
the count. Brown motion 6 was granted, and Brown Motion 5 was granted-in-part to add
claims 57-58 and 60 to the Brown application and designate them as corresponding to the
-3-
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007